Table 3.
Proportion of prostate cancer subjects with castration
| Degarelix | Goserelin | |
|---|---|---|
| FAS, n | 117 | 117 |
| Day 3, n | 117 | 116 |
| Number of patient with castrationa | 116 | 0 |
| Proportion, % (95% CI) | 99.1 (95.3, 100.0) | 0 (0.0, 3.1) |
| Day 7, n | 117 | 117 |
| Number of patient with castration | 117 | 0 |
| Proportion, % (95% CI) | 100 (96.9, 100.0) | 0 (0.0, 3.1) |
| Day 28, n | 116 | 115 |
| Number of patient with castration | 116 | 115 |
| Proportion, % (95% CI) | 100 (96.9, 100.0) | 100 (96.8, 100.0) |
a
Serum testosterone level ≤0.5 ng/mL. CI, confidence interval; FAS, full analysis set.